SCYNEXIS to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 10

11/3/21 8:30:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SCYX alert in real time by email

JERSEY CITY, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 10, 2021, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2021.

Conference call and webcast details:

Investors (domestic): (877) 705-6003

Investors (international): (201) 493-6725

Conference ID: 13724235

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1504710&tp_key=3a6a6b5742

A live audio webcast can be accessed by visiting the Investor Relations section of the Company's website, www.scynexis.com. A replay of the webcast will be archived on the SCYNEXIS website for 90 days following the event.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS scientists are developing the company's lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. SCYNEXIS has initiated the launch of its first commercial product in the U.S., BREXAFEMME ^® (ibrexafungerp tablets), which was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. In addition, late-stage clinical development of ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (rVVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing. For more information, visit www.scynexis.com.

CONTACT:

Investor Relations

Irina Koffler

LifeSci Advisors

Tel: (646) 970-4681

[email protected]

Media Relations

Gloria Gasaatura

LifeSci Communications

Tel: (646) 970-4688

[email protected]

Get the next $SCYX alert in real time by email

SCYNEXIS to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 10

Chat with this insight

Recent Analyst Ratings for $SCYX

$SCYX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

$SCYX Leadership Updates

Live Leadership Updates

AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti

SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update

SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch

$SCYX Financials

Live finance-specific insights

GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update

SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9

$SCYX SEC Filings

SCYNEXIS Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form 424B5 filed by SCYNEXIS Inc.

SEC Form 10-Q filed by SCYNEXIS Inc.

$SCYX Market Insights

Live Market Insights

SCYNEXIS Q1 2024 GAAP EPS $0.01 Beats $(0.20) Estimate, Sales $1.400M Beat $303.000K Estimate

SCYNEXIS Presented Preclinical Data On Second Generation Fungerp SCY-247 At The Congress Of The European Society Of Clinical Microbiology And Infectious Diseases

Cantor Fitzgerald Reiterates Overweight on SCYNEXIS

$SCYX Press Releases

Fastest customizable press release news feed in the world

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

$SCYX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$SCYX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

Aegis Capital reiterated coverage on SCYNEXIS with a new price target

Aegis Capital reiterated coverage on SCYNEXIS with a new price target

Maxim Group reiterated coverage on SCYNEXIS with a new price target

FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

$SCYX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Angulo Gonzalez David bought $27,400 worth of shares (20,000 units at $1.37), increasing direct ownership by 4% to 507,871 units (SEC Form 4)

Director Macdonald Guy was granted 23,000 shares, increasing direct ownership by 72% to 55,000 units (SEC Form 4)

Director Hastings David C was granted 23,000 shares, increasing direct ownership by 99% to 46,183 units (SEC Form 4)

$SCYX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Angulo Gonzalez David bought $27,400 worth of shares (20,000 units at $1.37), increasing direct ownership by 4% to 507,871 units (SEC Form 4)

Recent Analyst Ratings for
$SCYX

$SCYX
Large Ownership Changes

$SCYX
Leadership Updates

$SCYX
Financials

$SCYX
SEC Filings

$SCYX
Market Insights

$SCYX
Press Releases

$SCYX
Analyst Ratings

$SCYX
FDA approvals

$SCYX
Insider Trading

$SCYX
Insider Purchases